Verified factor-similar pair

MDYG vs VXF

These two ETFs meet the same FF6 US comparison criteria: US-listed equity ETFs, the same USD model basis, at least one material non-market factor, and 100% overlap in statistically significant material factor exposure.

SMB
Similarity score
85
Verified similar

The score combines exposure-level distance, factor-vector shape, market-beta closeness, and a small backtested relative-Sharpe term.

Quick Read

  • VXF has the higher backtested relative Sharpe (0.938 vs 0.890).
  • VXF has the lower published fee (0.05% vs 0.15%).
  • VXF is cheaper on dividend valuation (126 vs 170, where 100 is each fund's historical median).
  • VXF has the stronger regression fit (adjusted R-squared 0.972 vs 0.909).

These are screening signals, not a complete review of portfolio construction, turnover, taxes, or trading quality.

MDYG

State Street SPDR S&P 400 Mid Cap Growth ETF
SMB
Adj. R2
0.909
Rel. Sharpe
0.890
Mkt beta
1.03
AUM
US$2.6B
MER
0.15%
Valuation
170

VXF

Vanguard Extended Market ETF
SMB
Adj. R2
0.972
Rel. Sharpe
0.938
Mkt beta
1.03
AUM
US$26.8B
MER
0.05%
Valuation
126

Factor Exposure Match

Blue bars compare raw factor beta magnitude. Green bars compare absolute t-stat strength. Dim bars indicate the t-stat is below 1.96.

SMB
MDYG
+0.46
|t|
+10.4
VXF
+0.60
|t|
+26.3
diff -0.14
HML
MDYG
-0.07
|t|
-1.7
VXF
+0.02
|t|
+0.8
diff -0.09
RMW
MDYG
+0.11
|t|
+2.0
VXF
-0.05
|t|
-1.9
diff +0.16
CMA
MDYG
+0.01
|t|
+0.1
VXF
-0.13
|t|
-3.9
diff +0.13
UMD
MDYG
+0.03
|t|
+1.0
VXF
+0.02
|t|
+1.5
diff +0.01

Why This Pair Matches

Exposure level
81
Exposure shape
96
Mkt beta diff
0.01
Rel. Sharpe diff
0.048

This comparison focuses on measured factor exposure. It does not compare holdings methodology, turnover, tax handling, or issuer process. Backtested relative Sharpe is a secondary signal rather than a stand-alone forecast. See methodology.

MDYG fund page VXF fund page US ETF Leaders US Universe
Important context

VerifiedBeta publishes educational ETF research, not personalized investment advice, portfolio management, or security recommendations. Funds that screen well here can still be unsuitable for your objectives, taxes, liquidity needs, or constraints. Review fund documents, methodology assumptions, and your own circumstances before acting. See the full disclaimer.